Cepheid to Webcast Upcoming Financial Presentation

December 23, 2010

SUNNYVALE, Calif., Dec. 23, 2010 /PRNewswire-FirstCall/ — Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conference, and invited investors to participate via webcast.

                          J. P. Morgan Healthcare Conference
                 Thursday, January 13, 2011 at 11.00 a.m. Pacific Time

To access the live webcast for this event, please visit Cepheid’s website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

    For Media Inquiries:        For Investor Inquiries:
    --------------------        -----------------------
    Jared Tipton                Jacquie Ross
    Cepheid Corporate            Cepheid Investor
     Communications              Relations
    Tel: (408) 400-8377         Tel: (408) 400-8329
    communications@cepheid.com   investor.relations@cepheid.com

SOURCE Cepheid

Source: newswire

comments powered by Disqus